Therapy-related acute myeloid leukemia (t-AML) and therapy-related myelodysplastic syndrome (t-MDS) are well-recognized complications of cytotoxic chemotherapy and/or radiotherapy^[@R1]^. There are several features that distinguish t-AML from *de novo* AML including a higher incidence of *TP53* mutations^[@R2],[@R3]^, abnormalities of chromosomes 5 or 7, complex cytogenetics, and a reduced response to chemotherapy^[@R4]^. However, it is not clear how prior exposure to cytotoxic therapy influences leukemogenesis. In particular, the mechanism by which *TP53* mutations are selectively enriched in t-AML/t-MDS is unknown. Here, we show by sequencing the genomes of 22 cases of t-AML that the total number of somatic single nucleotide variants and percentage of chemotherapy-related transversions are similar in t-AML and *de novo* AML, indicating that prior chemotherapy does not induce genome-wide DNA damage. We identified four cases of t-AML/t-MDS where the specific *TP53* mutation was present at low frequencies (0.003--0.7%) in mobilized blood leukocytes or bone marrow 3--6 years prior to the development of t-AML/t-MDS, including two cases in which the relevant *TP53* mutation was detected prior to any chemotherapy. Moreover, functional *TP53* mutations were identified in small populations of peripheral blood cells of healthy chemotherapy-naïve elderly individuals. Finally, murine bone marrow chimeras containing both wild type and *Tp53*^+/−^ hematopoietic stem/progenitor cells (HSPCs) preferentially expanded after exposure to chemotherapy. These data suggest that cytotoxic therapy does not directly induce *TP53* mutations. Rather, they support a model in which rare HSPCs carrying age-related *TP53* mutations are resistant to chemotherapy and expand preferentially after treatment. The early acquisition of *TP53* mutations in the founding HSPC clone probably contributes to the frequent cytogenetic abnormalities and poor responses to chemotherapy that are typical of patients with t-AML/t-MDS.

T-AML/t-MDS are clonal hematopoietic disorders that typically develop 1--5 years following exposure to chemotherapy or radiotherapy^[@R1]^. To better understand how prior cytotoxic therapy contributes to the high incidence of *TP53* mutations and karyotypic abnormalities in t-AML/t-MDS, we sequenced the genomes of 22 cases of t-AML, including one case reported previously^[@R5]^. These data were compared to whole genome sequence data previously reported for *de novo* AML^[@R6]^ and secondary-AML (s-AML) arising from MDS not receiving previous chemotherapy except hydroxyurea^[@R7],[@R8]^. Of the sequenced t-AML cases, 23% had rearrangements of MLL, 23% complex cytogenetics, and 36% normal cytogenetics ([Extended Data Table 1](#T1){ref-type="table"} & [Suppl. Table 1](#SD1){ref-type="supplementary-material"}).

We predicted that DNA damage induced during exposure to cytotoxic therapy would manifest itself in t-AML genomes with an increased mutation burden. However, the total number of validated somatic single nucleotide variants (SNVs) and genic (tier 1) somatic SNVs identified was similar to that for *de novo* AML and s-AML ([Fig. 1a--b](#F1){ref-type="fig"}). Likewise, the number of small insertions or deletions (indels) in genic regions was similar in t-AML, *de novo* AML, and s-AML ([Fig. 1c](#F1){ref-type="fig"}). A prior study showed that transversions are specifically enriched in relapsed AML following chemotherapy^[@R9]^. However, the percentage of transversions, and in fact of all six classes of SNVs, was similar in all three cohorts ([Fig. 1d--e](#F1){ref-type="fig"}). Structural variants and somatic copy number alterations were uncommon in these t-AML cases ([Suppl. Table 2](#SD2){ref-type="supplementary-material"} and [Extended Data Fig. 1A](#F5){ref-type="fig"}). Moreover, the number of identifiable subclones in t-AML was similar to that observed in *de novo* AML ([Fig. 1f](#F1){ref-type="fig"} and [Extended Data Fig. 1B](#F5){ref-type="fig"}). Collectively, these data show that the mutation burden of t-AML genomes is similar to that of *de novo* AML genomes.

We next asked whether the pattern of genes frequently mutated in t-AML/t-MDS is distinct from that observed in *de novo* AML/MDS. Whole genome sequencing identified an average of 10.2 ± 7.1 missense, nonsense, in-frame indel, or frameshift mutations per t-AML genome ([Suppl. Table 3](#SD3){ref-type="supplementary-material"}). To better define the frequency of specific mutations in t-AML/t-MDS, we sequenced a panel of 149 "AML/MDS" genes in an additional 89 patients with t-AML or t-MDS ([Suppl. Table 4](#SD4){ref-type="supplementary-material"}). We combined the whole genome sequence data with the extension series to report on 52 cases of t-AML and 59 cases of t-MDS. Abnormalities of chromosome 5 or 7 or complex cytogenetics were present in 55.0% of cases ([Extended Data Table 2](#T2){ref-type="table"} & [Suppl. Table 1](#SD1){ref-type="supplementary-material"}). The t-AML/t-MDS data were compared to 199 previously reported *de novo* AML genomes or exomes^[@R6]^ or 150 previously reported cases of *de novo* MDS in which extensive candidate gene sequencing was performed^[@R8]^. As reported previously, *TP53* mutations are significantly enriched in t-AML/t-MDS compared with *de novo* AML/MDS ([Fig. 1g--h](#F1){ref-type="fig"} and [Suppl. Table 5](#SD5){ref-type="supplementary-material"}). Interestingly, mutations of ABC transporter genes, a subset of which have been implicated in chemotherapy resistance, also are enriched in t-AML versus *de novo* AML. On the other hand, several well-defined driver gene mutations (i.e., *DNMT3A* and *NPM1*) were significantly less common in t-AML. Thus, although the total mutation burden is similar, a distinct subset of mutated genes is present in t-AML/t-MDS.

*TP53* is the most commonly mutated gene in t-AML/t-MDS with 33.3% of patients affected in our series ([Fig. 1g--h](#F1){ref-type="fig"}); the vast majority of these mutations have previously been identified as pathogenic^[@R10]^. Multivariate analysis revealed that *TP53* mutations were associated with poor risk cytogenetics and a worse prognosis ([Suppl. Tables 6](#SD6){ref-type="supplementary-material"} & [7](#SD7){ref-type="supplementary-material"} and [Extended Data Fig. 2](#F6){ref-type="fig"}), both hallmarks of t-AML/t-MDS. These observations suggest a central role for *TP53* mutations in the pathogenesis of many cases of t-AML/t-MDS. However, the mechanism by which *TP53* mutations are selectively enriched in t-AML/t-MDS is unclear. The mutation burden in the genomic region containing *TP53* (including silent Tier 1, Tier2, and Tier 3 mutations) is similar between t-AML and *de novo* AML ([Extended Fig. 1C](#F5){ref-type="fig"}). Thus, it is not likely that chemotherapy directly induces *TP53* mutations. We recently reported that individual HSPCs accumulate somatic mutations as a function of age, such that by age 50, there are on average 5 coding gene mutations per HSPC^[@R11]^. Based on this data and on current estimates that there are approximately 10,000 HSCs in humans^[@R12]^, we predict that 44% of healthy individuals at 50 years of age may have at least one HSPC that carries a randomly generated, functional *TP53* mutation (see extended Methods). *TP53* plays a central role in regulating cellular responses to genotoxic stress^[@R13]--[@R17]^, and loss of *TP53* provides a selective advantage for neoplastic growth^[@R18]^. Together, these observations suggest a model in which rare HSPCs carrying age-related *TP53* mutations are resistant to chemotherapy and expand preferentially after treatment ([Extended Data Fig. 3](#F7){ref-type="fig"}).

This model suggests the following testable predictions: 1) in patients with t-AML containing clonal *TP53* mutations, HSPCs harboring the specific *TP53* mutation will be present long before the development of overt t-AML; 2) somatic *TP53* mutations will be present in the HSPCs of some healthy individuals never exposed to cytotoxic therapy; and 3) HSPCs harboring *TP53* mutations will expand under the selective pressure of chemotherapy.

To test the first prediction, we identified 7 cases of t-AML/t-MDS with specific *TP53* mutations for whom we had leukapheresis or bone marrow specimens banked 3--8 years prior to the development of t-AML/t-MDS ([Extended Table 3](#T3){ref-type="table"}). Of note, in all the cases, the *TP53* mutation was clonal in the t-AML/t-MDS diagnostic sample. Current next-generation sequencing (NGS) technology is limited in the detection of rare variant alleles due to an intrinsic sequencing error rate of \~ 0.1%^[@R19]^. To overcome this limitation, we introduced random bar codes during production of the sequencing libraries, such that sequence "read families" containing unique bar codes are generated ([Extended Fig. 4a](#F8){ref-type="fig"}). Using tumor DNA with a known *TP53* mutation, we show that this assay can detect a variant allele with a frequency of 0.009% ([Extended Fig. 4b--c](#F8){ref-type="fig"}).

The specific *TP53* mutation present in the diagnostic t-AML/t-MDS sample was identified in prior-banked specimens in four out of the seven cases tested (see Supplementary Materials for case presentations); in the other three cases, we were unable to detect the diagnostic *TP53* mutation in the prior banked blood or bone marrow sample; it is not clear whether these mutations were present but below our limit of detection or were truly absent. Patient 530447 developed t-AML after an autologous stem cell transplant for refractory Hodgkin\'s lymphoma ([Fig. 2A](#F2){ref-type="fig"}). The diagnostic t-AML sample carried biallelic mutations of *TP53*, missense mutations of *TET2* and *NUP9*8, a silent mutation of *CSMD1*, and a subclonal *KRAS* mutation. Analysis of a leukapheresis sample obtained 6 years prior to the development of t-AML revealed that both *TP53* mutant alleles were present with a variant allele fraction (VAF) of approximately 0.5% ([Fig. 2b](#F2){ref-type="fig"}). The *CSMD1* mutation was also present at the same VAF and is likely a passenger mutation. However, two potential driver mutations (*TET2* and *NUP98*) were not detectable in the prior banked sample. Thus, these data show that, in this patient, the biallelic *TP53* mutations preceded the development of t-AML by at least six years and antedated the development of the *TET2* and *NUP98* mutations ([Fig. 2c](#F2){ref-type="fig"}). In a second case (patient 341666), a heterozygous *R196*\* *TP53* mutation was identified in mobilized peripheral blood leukocytes 3 years prior to the development of t-MDS at a frequency of 0.1%, preceding the acquisition of a *RUNX1* mutation ([Extended Data Fig. 5](#F9){ref-type="fig"}).

In two of the four cases, the prior banked sample was obtained prior to the initiation of chemotherapy. Patient 967645 developed t-AML 5 years after the diagnosis of marginal zone lymphoma ([Fig 3a](#F3){ref-type="fig"}). The diagnostic t-AML sample contained a homozygous *Y220C TP53* mutation. Using a droplet digital PCR (ddPCR) assay, we identified the same *Y220C TP53* mutation in a bone marrow sample obtained before any chemotherapy at a frequency of 0.0027% (average of two independent experiments) ([Fig 3b](#F3){ref-type="fig"}). We next asked whether other mutations in the diagnostic t-AML sample also were present in this prior banked sample ([Suppl. Table 8](#SD8){ref-type="supplementary-material"}). We focused on *G155S SNAP25*; this mutation is likely a non-pathogenic mutation as this gene is not expressed in AML samples^[@R6]^. Indeed, we identified the *G155S SNAP25* mutation in the prior banked bone marrow sample with a similar VAF (0.0029%) as that for *Y220C TP53* ([Fig 3c](#F3){ref-type="fig"}). Of note, del 5 and del 7 were subclonal at diagnosis (present in 54% and 38% of metaphases, respectively) ([Suppl. Table 1](#SD1){ref-type="supplementary-material"}). Collectively, these data provide evidence that an HSPC harboring a Y220C *TP53* mutation preferentially expanded after chemotherapy with the subsequent acquisition of del 5 and then del 7 ([Fig 3d](#F3){ref-type="fig"}). Of note, we found two other cases of t-AML/t-MDS with clonal *TP53* mutations but subclonal del 5 and/or del 7 (UPNs 756582 and 837334, [Suppl. Table 1](#SD1){ref-type="supplementary-material"}). Together, these data suggest that *TP53* mutations precede the development of these characteristic cytogenetic abnormalities of t-AML/t-MDS.

In a second case, patient 895681 developed t-MDS 3.5 years after the initiation of chemotherapy for Non-Hodgkin\'s lymphoma ([Fig 3e](#F3){ref-type="fig"}). The diagnostic t-MDS sample contained a clonal *TP53* H179L mutation. Using ddPCR, we identified *TP53* H179L at a VAF of 0.05% in a bone marrow sample taken prior to the initiation of cytotoxic therapy ([Fig 3f](#F3){ref-type="fig"}). Thus, as with patient 967645, a HSPC carrying a functional *TP53* mutation was present prior to cytotoxic therapy exposure, later giving rise to the malignant t-AML/t-MDS clone ([Fig 3g](#F3){ref-type="fig"}).

To determine whether HSPCs harboring *TP53* mutations are present in healthy individuals, we analyzed peripheral blood leukocytes from 20 elderly (68---89 years old) cancer-free donors who had not received prior cytotoxic therapy. We limited our sequencing to exons 4--8 of *TP53* since the majority of pathogenic mutations in *TP53* are located in these exons. Using our unique adaptor sequencing assay, we identified *TP53* mutations in 9 of 19 evaluable cases, with VAFs ranging from 0.01% to 0.37% ([Extended Table 4](#T4){ref-type="table"}). Of note, since we did not sequence the entire coding region of *TP53*, it is likely that our study underestimates the true frequency of healthy elderly individuals harboring HSPCs with *TP53* mutations. Droplet digital PCR confirmed the presence of the *TP53* mutation in all three cases that were tested ([Extended Fig. 6](#F10){ref-type="fig"}). Interestingly, the majority of the *TP53* mutations identified are known pathogenic mutations previously implicated in cancer. These data suggest that functional *TP53* mutations may confer (even in the absence of cytotoxic therapy) a subtle competitive advantage that results in modest HSPC expansion over time.

To directly test the hypothesis that functional *TP53* mutations confer a survival advantage after chemotherapy, we generated mixed bone marrow chimeras containing both wild type and *Tp53*^+/−^ cells ([Fig. 4a](#F4){ref-type="fig"}). In mice treated with vehicle control, we observed a non-significant trend towards increased *Tp53*^+/−^ donor contribution to hematopoiesis ([Fig 4b--e](#F4){ref-type="fig"}). Whether longer follow up would confirm a subtle competitive advantage, as suggested by the expansion of *TP53* mutant HSPC clones in elderly healthy individuals, will require additional study. Regardless, upon treatment with N-ethyl-N-nitrosourea, *Tp53*^+/−^ HSPCs display a competitive advantage. Importantly, a prior study similarly showed that *Tp53*^+/−^ HSCs also have a competitive advantage following irradiation, which appeared to be due, at least in part, to reduced irradiation-induced senescence in *Tp53*^+/−^ HSCs ^[@R20],[@R21]^.

There is increasing evidence that cancers undergo clonal evolution under the selective pressure of chemotherapy ^[@R22]^. For example, the clonal architecture of *de novo* AML is dynamic, with certain (often minor) subclones becoming dominant at relapse following chemotherapy ^[@R9]^. Here, we show that HSPCs that acquire heterozygous *TP53* mutations as a function of normal aging also are subject to Darwinian selection upon exposure to cytotoxic therapy, ultimately resulting in the expansion of HSPCs with these mutations. The high frequency (nearly 50%) of elderly individuals with detectable heterozygous *TP53* mutations in their circulating leukocytes far exceeds the prevalence of AML or MDS in this age group. Clearly, additional mutations, including mutation of the second *TP53* allele, are needed for transformation to AML or MDS. Consistent with this observation, only a minority of patients with Li Fraumeni syndrome, most of whom harbor germline heterozygous *TP53* mutations, develop AML or MDS ^[@R23]^. This model provides a potential mechanism for the high incidence of *TP53* mutations in t-AML/t-MDS^[@R24]^. The *TP53* mutation in the founding clone likely contributes to the frequent cytogenetic abnormalities and poor response to chemotherapy that are typical of t-AML/t-MDS. For t-AML/t-MDS cases that do not harbor *TP53* mutations, it will be important to determine whether different age-related mutations also confer a competitive advantage to HSPCs that are exposed to cytotoxic therapy and to define the nature of these mutations.

METHODS {#S1}
=======

Patient Characteristics {#S2}
-----------------------

For the whole genome sequencing study, we intentionally selected the original 22 cases of t-AML to have minimal numbers of cytogenetic abnormalities. However, the additional 89 cases of t-AML/t-MDS were randomly selected from those samples with sufficient tumor and skin DNA. All patients were selected from a larger cohort of adult AML and MDS patients enrolled in a single institution tissue banking protocol that was approved by the Washington University Human Studies Committee (WU HSC\#01-1014). Written informed consent for whole genome sequencing was obtained from all study participants. Patients were treated in accordance with NCCN guidelines ([www.nccn.org](http://www.nccn.org)) with an emphasis on enrollment in therapeutic clinical trials whenever possible. Clinical data for all patients, including the pre-existing condition requiring cytotoxic therapy, the cytotoxic therapy received prior to the t-AML/t-MDS diagnosis, cytogenetics, treatment approach, and outcomes data, are presented in [Extended Table 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"} & [Suppl. Table 1](#SD1){ref-type="supplementary-material"}. Peripheral blood leukocyte genomic DNA from cancer-free individuals (median age = 75.3 ± 6.6 years) was obtained as part of a Washington University Institutional Review Board-approved protocol. All subjects had no previous history of invasive cancer or treatment with cytotoxic therapy, as determined by the medical history.

Whole genome sequencing and variant detection {#S3}
---------------------------------------------

The procedure described by Mardis et al^[@R25]^ was followed for library construction and whole genome sequencing. Briefly, Illumina DNA sequencing was used to generate sequence that covered the haploid reference at a depth between 30.51 and 72.60 ([Suppl. Table 9](#SD9){ref-type="supplementary-material"}). Sequence data was aligned to reference sequence build NCBI-human-build36 using bwa version 0.5.5^[@R26]^ (params: -t 4) then merged and deduplicated using picard version 1.29. We detected SNVs using the intersection of samtools version r963^[@R27]^ (params: -A -B) and Somatic Sniper v0.7.3^[@R28]^ (params: -q 1 -Q 15) and filtered to remove false-positives (params: min-base-quality 15, minmapping-quality 40, min-somatic-score 40). Indels were detected using GATK version 5336^[@R29]^ unioned with Pindel version 0.5^[@R30]^. Somatic copy number alterations were detected using copyCat version 1.5 (<http://github.com/chrisamiller/copycat>). We detected structural variants using BreakDancer version 1.2^[@R31]^ and SquareDancer version 0.1 (<https://github.com/genome/gms-core/blob/master/lib/perl/Genome/Model/Tools/Sv/SquareDancer.pl>) followed by assembly with Tigra-SV (<http://gmt.genome.wustl.edu/tigra-sv/0.1/index.html>). SciClone (in review - <http://github.com/genome/sciclone>) was used to infer the subclonal architecture of all WGS samples.

Validation and extension sequencing with variant detection {#S4}
----------------------------------------------------------

We used custom sequence capture arrays from Roche Nimblegen that targeted variants detected by whole genome sequencing and extended this array to cover all coding exons from an additional 149 genes of interest ([Suppl. Table 4](#SD4){ref-type="supplementary-material"}). Libraries were prepared, sequence was generated, and somatic alterations identified as described for whole genome sequencing, with the addition of VarScan v2.2.6^[@R32]^ (params: \--min-var-freq 0.08 \--p-value 0.10 \--somatic-p-value 0.01 -validation) as a variant caller for both SNVs and indels. On average, genes were covered with a depth of 58.3 ([Suppl. Table 10](#SD10){ref-type="supplementary-material"}). Biallelic TP53 mutations in case 530447 were confirmed with PCR amplification of the genomic region containing both somatic mutations from the diagnostic t-AML sample. The resulting amplicons were cloned into the pCR-TOPO plasmid vector (Life Sciences) and sequenced using Sanger sequencing.

Statistical analyses {#S5}
--------------------

Fisher\'s Exact tests were used to evaluate the association between pairs of dichotomous variables, with a significant right-sided p-value indicating a positive relationship and a significant left-sided p-value indicating a negative relationship. The relationship between overall survival and each discrete measure was tested with Kaplan-Meier survival analyses with separate analyses for the AML and MDS groups. Age at diagnosis was discretized into quartiles for each group. Multivariate proportional-hazards regression models were created separately for the AML and MDS groups. All variables with log-rank p-values of 0.20 or less in the Kaplan-Meier analyses were included in the first step. In successive steps, the variable with the largest p-value was removed and the model re-run until all remaining variables had p-values of 0.05 or less. Two-way interactions among the remaining variables were examined. Variables removed in earlier steps were added back to the model one at a time to determine if they significantly improved the final model. The proportionality assumption was evaluated for each variable in the final models.

Rare variant detection using unique adaptor next generation sequencing (NGS) {#S6}
----------------------------------------------------------------------------

Amplicons approximately 200 bp in length were prepared from patient genomic DNA samples using primers designed to amplify genomic regions harboring known tumor-specific SNVs ([Suppl. Table 11](#SD11){ref-type="supplementary-material"}). These amplicons were prepared for NGS using the Illumina TruSeq DNA Sample Preparation Kit (Illumina Catalog \#FC-121-2001) replacing the kit adapters with adapters containing a random nucleotide index sequence. Libraries were quantified using the Agilent qPCR NGS Library Quantification Kit, Illumina GA (Agilent Technologies Catalog \#G4880A). Using this quantification, each library was diluted to ensure that each random index would be observed in multiple sequenced reads^[@R33],[@R34]^. Each diluted library was amplified and sequenced on the Illumina MiSeq platform. Sequenced reads containing the same index sequence were grouped together creating "read families" in a manner similar to established methods^[@R33],[@R34]^. Reads within a read family were aligned against each other to filter out stochastic sequencing errors generating an error-corrected read family consensus sequence. Each consensus sequence was locally-aligned to UCSC hg19/GRCh37 using bowtie2^[@R35]^ with the default settings. The aligned read families were processed with Mpileup^[@R27]^ using the parameters --*BQ0 --d 10000000000000*. Next, variants were called with VarScan^[@R32]^ using the parameters \--min-coverage 10000 \--min-reads2 10 \--min-avg-qual 0 \--min-var-freq 0 \--p-value 1. Variant allele frequencies for the expected mutations and the background error rate were visualized using IGV^[@R36]^ and graphically represented using ggplot2^[@R37]^. Variant coordinates are displayed in hg18/GRCh36.

Detection of somatic *TP53* mutations in cancer free subjects using unique adaptor NGS {#S7}
--------------------------------------------------------------------------------------

Amplicons were prepared from healthy control genomic DNA samples using primers designed to amplify exons four through eight of *TP53* ([Suppl. Table 11](#SD11){ref-type="supplementary-material"}). Patient specific barcodes, six nucleotides in length, were appended to the 5-prime end of each primer to enable pooling of multiple samples for sequencing. Amplicons generated from each *TP53* exon/patient sample combination were generated as previously described and purified products were pooled in equimolar amounts. The pooled barcoded amplicons were prepared for error-corrected sequencing as previously described. Sequencing was completed on the Illumina Hi-Seq 2500 platform. Sequenced reads were demultiplexed based on the known patient-specific barcode sequences using a two nucleotide hamming distance. Demultiplexed sequence reads were organized into read families based on their random oligonucleotide index sequence and error-corrected as outlined previously. Read families comprised of three reads or more were used for analysis. A binomial distribution of the substitution rate at each covered base in *TP53* was used to identify individuals with somatic *TP53* mutations. A variant was called if it met the following criteria: 1) the binomial p-value was less than 10^−6^; 2) the VAF was greater than 1:10,000; 3) at least 10,000 unique read families were sequenced at the position of interest; 4) at least 10 read families called the variant; and 5) the VAF in the individual was greater than five times the mean VAF for all individuals with greater than 10,000x coverage at that specific nucleotide. Read families from one patient sample (barcode GTACGGC) were removed from analysis due to a high error rate. All somatic mutations were identified in this manner except for *TP53* Y220C, which received closer manual inspection due to the large number of these mutations observed in our t-AML cohort.

Extraction of genomic DNA from FFPE samples {#S8}
-------------------------------------------

Genomic DNA was extracted from FFPE samples with the QIAamp DNA FFPE Tissue Kit. Because of the effects of formalin fixation (cross-linking, DNA fragmentation, etc.), the amount of amplifiable DNA per sample was less than would be expected with Qubit® fluorometric quantitation. As such, ddPCR was used to quantify the amount of amplifiable genomic DNA per sample such that the number of amplifiable domains tested were comparable between experimental and control samples.

Droplet digital PCR {#S9}
-------------------

All primers and probes for droplet digital PCR were designed by Bio-Rad per MIQE guidelines^[@R38]^. In the case of *TP53* Y220C, the *TP53* region of interest in exon 6 was amplified with the following primers: 5\'-TTTTCGACATAGTGTGGTG-3\' and 5\'-CTGACAACCACCCTTAAC-3\'. The 5\'-Hex/TGCCCTATGAGCCGCCT/Iowa Black FQ® -3\' probe was used to detect the wild-type allele and the 5\'-FAM/CCCTGTGAGCCGCCTGA/Iowa Black FQ®-3\' probe was used to detect the mutant allele. All reagents were purchased from Bio-Rad. Droplet digital PCR was performed as previously described^[@R39]^. Specifically, quantitative PCR was performed with 900 nM-1800 nM forward and reverse primers, 250 nM mutant and wild-type genomic probes, and 2--4 ng/μl genomic DNA. Quantitative PCR was performed with annealing/extension temperatures of 55.5--60°C × 40 cycles. For droplet generation and analysis, we used the Bio-Rad QX100™ and QX200™ Droplet Digital™ PCR Systems.

Due to the fact that DNA degradation with time (i.e. guanosine oxidation, cytosine deamination) is known to interfere with rare allele detection^[@R34]^, we only identified variant alleles present in droplets also lacking the reference allele. This greatly increased the specificity of our calls by removing droplets in which one of the two DNA strands may have been chemically altered. At low variant allele frequency, it was assumed that only a single variant allele was present in these "mutant only" drops. Droplet allele distribution follows a Poisson distribution such that the number of droplets only containing a single allele (either variant or reference) can be determined from the percentage of empty droplets. Of note, droplets showing evidence of template independent amplification (i.e., observed in "no template controls") were counted as empty droplets. The VAF was determined from the fraction of the single allele droplets containing the variant allele. When appropriate, control samples were used to subtract potential background signal. VAFs calculated in this method were highly concordant with VAFs obtained through unique-adaptor NGS.

Generation and analysis of *Tp53*^+/−^ bone marrow chimeras {#S10}
-----------------------------------------------------------

*Tp53*^+/−^ and wild type mice were in bred on a C57BL/6 strain. Bone marrow from *Tp53*^+/−^ mice expressing *Ly5.2* was mixed at a 1:7 ratio with bone marrow from wild-type mice expressing *Ly5.1* and transplanted retro-orbitally into lethally irradiated *Ly5.1/5.2* recipients. *Tp53*^+/−^ and wild-type donors were both age (6--12 weeks) and sex matched (female). A total of 3 × 10^6^ cells were injected per recipient mice. Recipient mice were conditioned with 1000--1100 cGy from a ^137^Cesium source at a rate of approximately 95 cGy/minute before transplantation. Prophylactic antibiotics (trimethoprim-sulfamethoxazole; Alpharma, East Bridgewater, NJ) were given during the initial 2 weeks after transplantation. Five weeks after transplantation, mice were given two doses of N-Nitroso-N-ethylurea (ENU, 100 mg/kg;Sigma-Aldrich, St. Louis, MO) or vehicle alone intraperitoneally 9 days apart. Mice were stratified according to *Tp53*^+/−^ chimerism and then randomly distributed into the ENU and vehicle controls such that both cohorts had similar levels of *Tp53*^+/−^ chimerism at baseline. ENU and placebo were delivered in a final solution with 10% DMSO, 90 mM sodium citrate, and 180 mM sodium phosphate, pH 5.0. Peripheral blood chimerism was measured prior to ENU administration and 4--12 weeks after ENU administration. The investigator was not blinded. Mice were euthanized and bone marrow chimerism analyzed 12 weeks after ENU administration. The desired cohort size was determined based on observations from previously reported experiments^[@R20]^, and two independent experiments were performed. Mice were maintained under standard pathogen free conditions according to methods approved by the Washington University animal studies committee.

Flow cytometry {#S11}
--------------

Flow cytometry data were collected on a Gallios 10-color, 3-laser flow cytometer (Beckman Coulter) and analyzed with FlowJo software (Treestar). Cells were stained by standard protocols with the following antibodies (eBiosciences unless otherwise noted): Ly5.1 (A20, CD45.1), Ly5.2 (104, CD45.2), Ly6C/G (RB6-8C5, Gr-1), CD3e (145-2C11), CD45R (RA3-6B2, B220), CD11c (N418), TER-119, CD41 (MWReg30), CD117 (ACK2, c-kit), and Ly-6A/E (D7, Sca).

Estimation of TP53 mutation frequency in aging stem cells {#S12}
---------------------------------------------------------

The frequency and profile of somatic single nucleotide mutations in the HSCs of normal individuals have been previously measured. The somatic mutational burden is aging-related, and the estimated rate of mutagenesis obtained from this study was 3.2 × 10^−9^ mutations/nucleotide/year (95% CI 2.4 -- 4.0 × 10^−9^) for the average nucleotide in the exome. Thus, we would predict an average 50 year old to have 1.6 × 10^−7^ mutations/position. These mutations would not be randomly distributed but biased (in particular towards C to T/G to A transitions). It has been previously proposed that an individual possesses approximately 10,000 distinct HSCs. We used a randomized Monte Carlo simulation to model the prevalence of somatic single nucleotide mutations in healthy 50 year olds with 10,000 HSCs given a normal somatic mutational profile and mutation rate. Repeated simulation (n=100,000) allowed us to predict the distribution of aging-induced *TP53* (NM_000546) somatic mutations. As expected, this simulation modeled a Poisson process. We classified TP53 mutations as likely to be functional if they fulfilled both of the following criteria. First, we analyzed the mutations using the SIFT program (<http://sift.jcvi.org>) and required a SIFT score \<=0.05. Second, we required that the somatic mutations be reported at least once if a nonsense mutation or at least twice if a missense mutation in the IARC *TP53* database (<http://p53.iarc.fr>). Based on this simulation, we predict that 44% of 50 year-old individuals harbor one or more HSCs with a functional *TP53* mutation.

Extended Data {#S13}
=============

![Whole genome sequencing analysis of tAML\
**a**, Somatic copy number alterations in the 22 cases of t-AML. Blue indicates copy number loss. Red indicates copy number gain. **b**, Representative clonality plots for 8 cases of t-AML are shown. Scatter plots (lower panel) show variant allele frequency and read depth in the tumor sample. Variant alleles in the founding clone are depicted as green, while variants in subclones are depicted as orange or purple. The upper panels contain kernel density plots of the VAF data (green line) along with the posterior predictive densities (grey line) from the mathematical model used to segregate clusters. **c**, Frequency of Tier 1 silent, Tier 2, and Tier 3 mutations in 1 Mb increments across chromosome 17 in *de novo* AML and t-AML. The *TP53* genomic locus is identified.](nihms-635306-f0001){#F5}

![*TP53* mutations are associated with decreased overall survival in t-AML/t-MDS\
**a**, Overall survival in *TP53* mutated (n=13) and *TP53* wildtype (n=39) t-AML patients. **b**, Overall survival in *TP53* mutated (n=24) and *TP53* wildtype (n=35) t-MDS patients.](nihms-635306-f0002){#F6}

![Model of how cytotoxic therapy shapes clonal evolution in t-AML/t-MDS\
Age-related mutations in hematopoietic stem/progenitor cells (HSPCs) result in the production of a genetically heterogeneous population of HSPCs, including rare HSPCs with heterozygous *TP53* mutations in some individuals. During chemotherapy and/or radiotherapy for the primary cancer, HSPC clones harboring a *TP53* mutation have a selective growth advantage, resulting in expansion of that clone. Subsequent acquisition of additional driver mutations results in transformation to t-AML/t-MDS. Of note, the presence of *TP53* mutations likely accounts for this high incidence of cytogenetic abnormalities in t-AML/t-MDS and poor response to chemotherapy.](nihms-635306-f0003){#F7}

![Validation of the unique adaptor sequencing method\
**a**, Unique adaptor sequencing approach. Step 1: Genomic DNA is amplified with *TP53*-specific primers (green) with subpopulation-specific variant alleles highlighted in red. Step 2: Randomly indexed adapters (tan and gray) are ligated to each amplicon. Step 3: The indexed amplicons are amplified to generate multiple reads possessing the same bar code (i.e., read families). Step 4: After sequencing, reads are aligned and grouped by read families to generate an error-corrected consensus sequence. Sequencing errors (yellow) are randomly distributed amongst read families, while true variant alleles (red) are present in all members of a given read family. **b**, A tumor sample (UPN 895681) with a known *TP53* somatic mutation (chromosome 17: 7519119 T to A) at a variant allele frequency (VAF) of \~37% was mixed with normal genomic DNA sample at the indicated ratio, and conventional (left panel) or unique adaptor next generation sequencing (middle and right panels) was performed, as described in Methods. DNA degradation with time may result in errors which are then amplified during PCR, providing a source of false positive calls. This is particularly true for C to A transversions. Since none of the *TP53* mutations analyzed in this study were C to A transversions, we also analyzed the data after removing C to A calls (right panel). The *TP53* variant allele is circled in blue. **c**, The threshold of detection for the variant allele with each sequencing method is shown.](nihms-635306-f0004){#F8}

![Clonal evolution in case 314666\
**a**, Clinical course of case 341666. **b**, Unique adaptor sequencing was performed on genomic DNA derived from a leukapharesis samples obtained 3 years prior to the diagnosis of t-MDS for the two clonal mutations present in the diagnostic t-AML sample. Genomic DNA from a patient lacking these variants was used as a control. The blue circle indicates the position of the variant SNV. **c**, Proposed model of clonal evolution to t-MDS in this case.](nihms-635306-f0005){#F9}

![Droplet digital PCR verification of selected somatic *TP53* mutations identified in peripheral blood of cancer-free individuals\
Droplet digital PCR was performed on genomic DNA isolated from the peripheral blood of cancer-free individuals (middle panel) for whom unique-read adaptor sequencing suggested the presence of the indicated *TP53* mutation. Controls represent peripheral blood DNA from cancer-free elderly individuals with variant allele frequencies not above background levels for the mutation of interest (right panel); the negative control for *Y220C TP53* is shown in [Fig. 3b](#F3){ref-type="fig"}. The diagnostic t-AML sample from patient 967645 was used as a positive control for *Y220C TP53* (**a**). For V173M *TP53* (**b**) and I195T *TP53* (**c**) double-stranded genomic blocks (gBlocks) were synthesized containing the mutation of interest and mixed with gBlocks of wild-type sequence. Droplets containing only the variant *TP53* allele are highlighted in orange, droplets containing the wild type *TP53* allele (with or without *the* variant *TP53* allele) are highlighted in blue; empty droplets are gray. The number of droplets in each gate is indicated.](nihms-635306-f0006){#F10}

###### Clinical summary of the 22 t-AML whole genome sequencing cases

Latency is defined as the time from the original cancer diagnosis to the development of t-AML/t-MDS.

  -------------------------------------------------- ----------------------- -----------------------
  **Age**                                            Median                  56.5 years (26--80)
                                                                             
  **Gender**                                         Male                    36.4%
  Female                                             63.6%                   
                                                                             
  **Prior Disease**                                  Breast                  45.5%
  Non-Hodgkin\'s Lymphoma                            13.6%                   
  Multiple Sclerosis                                 9.1%                    
                                                                             
  **Known Previous Treatment**                       Other                   31.8%
  Alkylator                                          45.5%                   
  Topoisomerase inhibitor                            63.6%                   
  Radiation                                          68.2%                   
  Autologous Transplant                              9.1%                    
                                                                             
  **Latency**                                        Median                  3.2 years (0.9--13.3)
                                                                             
  **Cytogenetics**                                   complex                 22.7%
  MLL rearrangement                                  22.7%                   
  non-complex non-MLL                                63.6%                   
                                                                             
  **% Blasts in the bone marrow**                    Median                  79% (19--95%)
                                                                             
  **Most intensive t-AML/t-MDS treatment regimen**   Allogeneic transplant   27.3%
  Myeloablative                                      40.9%                   
  Non-myeloablative                                  13.6%                   
  Other/unknown                                      18.2%                   
                                                                             
  **Remisison**                                      Yes                     50%
  No                                                 40.9%                   
                                                                             
  **Overal Survival**                                Median                  140.5 days (8--2000)
  -------------------------------------------------- ----------------------- -----------------------

###### Clinical summary of the combined 111 t-AML/t-MDS cases

Latency is defined as the time from the original cancer diagnosis to the development of t-AML/t-MDS.

  ------------------------------------------ ----------------------- ------------------------
  **Age**                                    Median                  61 years (18--82)
                                                                     
  **Gender**                                 Male                    53.2%
  Female                                     46.8%                   
                                                                     
  **Prior Disease**                          Breast                  29.7%
  Non-Hodgkin\'s Lymphoma                    24.7%                   
  Hodgkin\'s Disease                         22.5%                   
  Other                                      37.8%                   
                                                                     
  **Known Previous Treatment**               Alkylator               55.9%
  Topoisomerase inihbitor                    50.5%                   
  Radiation                                  63.1%                   
  Autologous Transplant                      21.6%                   
                                                                     
  **Latency**                                Median                  6.25 years (0.4--40.7)
                                                                     
  **Diagnosis**                              Leukemia                46.8%
  MDS                                        53.2%                   
                                                                     
  **Cytogenetics**                           deletion 5              26.1%
  deletion 7                                 28.8%                   
  complex                                    45.0%                   
  MLL rearrangement                          5.4%                    
  other/unknown                              41.4%                   
                                                                     
  **% Blasts in the bone marrow**            Median                  13% (0--95%)
                                                                     
  **Most intensive AML treatment regimen**   Allogeneic transplant   41.4%
  Myeloablative                              17.1%                   
  Non-myeloablative                          24.3%                   
  Other/unknown                              17.1%                   
                                                                     
  **Remisison**                              Yes                     49.5%
  No                                         43.2%                   
                                                                     
  **Overal Survival**                        Median                  414 days (8--3831)
  ------------------------------------------ ----------------------- ------------------------

###### Prior banked tissue samples in patients with t-AML/t-MDS with clonal *TP53* mutations

All patients had one or more clonal *TP53* mutation in their diagnostic t-AML/t-MDS samples (530447 had biallelic mutations). Cases in which the prior banked sample had detectable TP53 mutated cells are highlighted in red. See [Suppl. Table 1](#SD1){ref-type="supplementary-material"} for the clinical and molecular features of these cases. BM FFPE: formalin-fixed parafin-embedded sample; BM flow: snap frozen bone marrow leukocyte pellet.

  Patient   *TP53* mutation in t-AML/t-MDS   Prior banked tissue sample                                      
  --------- -------------------------------- ---------------------------- -------------------- ------ ------ ----------
  236041    7,518,261                        T to A                       R249W                2007   2011   BM FFPE
  341666    7,518,988                        G to A                       R196\*               2002   2005   Pharesis
  530447    7,519,238                        C to G                       K139N                2001   2007   Pharesis
  530447    7,518,263                        C to T                       R248Q                2001   2007   Pharesis
  648904    7,514,759                        C to T                       Exon 9 splice site   2001   2004   Pharesis
  756582    7,519,015                        C to T                       Exon 6 splice site   1999   2007   Pharesis
  895681    7,519,119                        T to A                       H179L                2000   2006   BM FFPE
  967645    7,518,915                        T to C                       Y220C                2005   2010   BM Flow

###### Somatic TP53 mutations in 19 cancer-free individuals. Coverage statistics are as follows

In the amplicon targeting exon 4, 17/19 subjects had \>10,000 coverage in 100% of the amplicon. In the amplicon targeting exon 5, 17/19 subjects had \>10,000 coverage in 100% of the amplicon. In the amplicon targeting exon 6, 5/19 subjects had \>10,000 coverage in 100% of the amplicon, and 11/19 subjects had \>10,000 coverage in at least 75% of the amplicon. In the amplicon targeting exon 7, 17/19 subjects had \>10,000 coverage in 100% of the amplicon. In the amplicon targeting exon 8, 18/19 subjects had \>10,000 coverage in 100% of the amplicon. See [Suppl. Table 11](#SD11){ref-type="supplementary-material"} for the primers used to make the amplicons from genomic DNA.

  Sample   Chr   Exon   Start     Stop      Ref   Var   Amino acid   COSMIC ID    Var count   Total read family count   VAF (read-family   VAF (ddPCR)
  -------- ----- ------ --------- --------- ----- ----- ------------ ------------ ----------- ------------------------- ------------------ -------------
  34       17    7      7518230   7518230   T     G     D259A        none         13          33085                     0.039%             N.D.
  99       17    7      7518273   7518273   C     T     G245S        COSM6932     18          41836                     0.043%             N.D.
  99       17    8      7517849   7517849   C     T     V272M        COSM10891    26          81015                     0.032%             N.D.
  269      17    8      7517845   7517845   C     T     R273H        COSM10660    489         420026                    0.12%              N.D.
  271      17    5      7519138   7519138   C     T     V173M        COSM11084    177         182809                    0.097%             0.081%
  271      17    5      7519174   7519174   C     T     A161T        COSM10739    25          164591                    0.015%             N.D.
  271      17    NA     7520035   7520035   A     T     SPLICING     COSM152274   23          165672                    0.014%             N.D.
  271      17    NA     7517934   7517934   C     T     INTRONIC     none         36          333996                    0.011%             N.D.
  273      17    6      7518990   7518990   A     G     I195T        COSM11089    57          15540                     0.37%              0.28%
  300      17    6      7518915   7518915   T     C     Y220C        COSM10758    91          316765                    0.029%             0.029%
  324      17    8      7517819   7517819   G     A     R282W        COSM10704    51          86090                     0.059%             N.D.
  335      17    7      7518264   7518264   G     C     R248G        COSM11564    245         218077                    0.11%              N.D.
  338      17    7      7518264   7518264   G     A     R248W        COSM10656    188         51001                     0.37%              N.D.
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![The mutational burden in t-AML is similar to *de novo* AML\
**a**, Total number of validated tier 1--3 somatic SNVs in t-AML (n=22), *de novo* AML (n=49), and s-AML (n=8). The mean ages of the t-AML, *de novo* AML, and s-AML cohorts were 55.7, 51, and 54.6 years respectively. **b**, Number of validated tier 1 somatic SNVs. **c**, Number of validated tier 1 small insertions/deletions (indels). **d**, Percentage of tier 1--3 somatic SNVs that are transversions. **e**, Mutational spectrum for all validated tier 1--3 somatic SNVs. **f**, Number of distinct clones per sample inferred from the identification of discrete clusters of mutations with distinct variant allele frequencies. **g**, Percentage of cases of t-AML (n=52) or *de novo* AML (n=199) harboring non-synonymous mutations of the indicated gene. **h**, Percentage of cases of t-MDS (n=59) or *de novo* MDS (n=150) harboring non-synonymous mutations of the indicated gene. ABC Fm: ABC family genes; NA: not available; s-AML: AML following MDS. ^+^P\<0.05 by one-way Anova. \*P\<0.05 by Fisher\'s Exact test. Data represent the mean ± SD.](nihms-635306-f0007){#F1}

![Bi-allelic *TP53* mutations are an early mutational event in the AML cells of UPN 530447\
**a**, Clinical course of case 530447. **b**, Unique adaptor sequencing of a leukapheresis sample obtained 6 years prior to the diagnosis of t-AML for each of the five clonal somatic SNVs identified in the diagnostic t-AML sample. Genomic DNA from a patient lacking these variants served as a control. The blue circle indicates the position of the variant SNV. **c**, Proposed model of clonal evolution to t-AML in this case.](nihms-635306-f0008){#F2}

![HSPC clones harboring somatic *TP5*3 mutations are detected in patients prior to cytotoxic therapy exposure\
**a**, Clinical course of case 967645. **b**, Dot plots of droplet digital PCR of a diagnostic t-AML sample from case 967645, a bone marrow sample from this patient obtained 5 years prior to the development of t-AML (prior to any cytotoxic therapy), or a control sample from a patient lacking a mutation in *TP53*. Droplets containing only the *Y220C TP53* allele are highlighted in orange, droplets containing wild type *TP53* (with or without *Y220C TP53*) are highlighted in blue; empty droplets are gray. The number of droplets in each gate is indicated. Data are representative of two independent experiments. **c**, Dot plots of droplet digital PCR data for *G155S SNAP25* using the same genomic DNA as in **b**. **d**, Proposed model of clonal evolution to t-AML in case 967645. **e**, Clinical course of case 895681. **f**, Dot plots of droplet digital PCR data of the diagnostic t-AML sample from case 895681, a bone marrow FFPE sample from this patient obtained 3.5 years prior to the development of t-MDS (prior to any cytotoxic therapy), or a control FFPE sample obtained from a patient lacking a mutation in *TP53*. The labeling scheme is the same as in **b**. **g**, Proposed model of clonal evolution to t-AML in case 895681; the diagnostic t-MDS sample contained a subclonal *ETV6* mutation.](nihms-635306-f0009){#F3}

![Heterozygous loss of *TP53* confers a clonal advantage to HSCs after exposure to ENU\
**a**, Experimental schema. Bone marrow chimeras were generated by transplanting a seven to one ratio of wild type to *Tp53*^+/−^ bone marrow into irradiated syngenic recipients. Following hematopoietic reconstitution (5 weeks) mice were treated with ENU or vehicle control as indicated. **b--d**, Shown is the percentage of total leukocytes (**b**), Gr-1^+^ neutrophils (**c**), or B220^+^ B cells (**d**) that were derived from *Tp53*^+/−^ cells. **e**, Percentage of Kit^+^ lineage^−^ Sca^+^ (KSL) cells in the bone marrow 12 weeks after ENU exposure that were derived from *Tp53*^+/−^ cells. Data represent the mean ± SEM of 11 and 14 mice in the ENU and vehicle cohorts respectively. Peripheral chimerism was analyzed using 2-way Anova and KLS chimerism with ANCOVA.](nihms-635306-f0010){#F4}
